130233-77-1

Basic information

• Product Name: 3-oxocyclobutane-1-carbonyl chloride
• CAS NO: 130233-77-1
• Molecular Weight: 132.546
• Mol File: 130233-77-1.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: 3-oxocyclobutane-1-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxocyclobutane-1-carbonyl chloride(130233-77-1)
• EPA Substance Registry System: 3-oxocyclobutane-1-carbonyl chloride(130233-77-1)

Safety Data

• Hazardous Substances Data: 130233-77-1(Hazardous Substances Data)

Upstream product

• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 79-37-8 oxalyl dichloride 
• 1191-95-3 cyclobutanone 

Relevant articles and documents

Conformationally restricted glutamic acid analogues: Stereoisomers of 1-aminospiro[3.3]heptane-1,6-dicarboxylic acid

All four stereoisomers of the title compound (1a-d) were prepared, starting from a common precursor, 3-oxocyclobutanecarboxylic acid. Lewis acid-catalyzed rearrangement of a 8-oxadispiro[2.0.3.1]octane-6-carboxylic acid derivative was used as the key synthetic step to construct the suitably functionalized spiro[3.3]heptane skeleton. A stabilized oxaphosphetane intermediate of the Wittig reaction was detected along the synthetic route. Separation of the diastereomeric intermediates allowed each target compound to be obtained as a single stereoisomer. The target compounds are all analogues of the glutamic acid; they mimic glutamate in a large array of restricted conformations, which might be used in mechanistic studies or in a systematic search for biologically active compounds.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Baeyer–Villiger monooxygenase-catalyzed desymmetrizations of cyclobutanones. Application to the synthesis of valuable spirolactones

A series of γ-butyrolactone derivatives, including some spiranic ones, was obtained through desymmetrization of the corresponding prochiral 3-substituted cyclobutanones via Baeyer–Villiger monooxygenase (BVMO)-catalyzed oxidation. After reaction optimization using several commercial enzymes, both antipodes of various lactones were synthesized in most cases with >90% conversion and >80% enantiomeric excess under mild reaction conditions. In some cases alcohol formation was also observed (up to 40% conversion) as an undesired side reaction due to the presence of alcohol dehydrogenases in these preparations. Selected transformations were achieved on a 100 mg scale showing the possibilities of these oxidative biocatalysts as a new source of highly interesting compounds.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.